Xu et al. demonstrated in 2018 that chemokine CC ligand 19 (CCL19) inhibits CRC angiogenesis by promoting miR-206 and thereby inhibiting the Met/ERK/HIF-1α/VEGF-A pathway [21]. This evidence concerns the gene MET and colorectal carcinoma.